| Co-Investigator(Kenkyū-buntansha) |
HASHIMOTO Shozo Univ. of Keio, School of Med., Prof., 医学部, 教授 (40050348)
KAMADA Rikisaburo Univ. of Nihon, School of Med, Prof., 医学部, 教授 (00058835)
SAKAMOTO Kiyohiko Univ. of Tohoku, School of Med. Prof., 医学部, 教授 (20014029)
IRIE Goro Univ. of Hokkaido, School of Med, Prof., 医学部, 教授 (30001788)
ABE Mitsuyuki Univ. of Kyoto, School of Med., Prof., 医学部, 教授 (00025587)
|
|---|
| Budget Amount *help |
¥11,900,000 (Direct Cost: ¥11,900,000)
Fiscal Year 1990: ¥5,000,000 (Direct Cost: ¥5,000,000)
Fiscal Year 1989: ¥6,900,000 (Direct Cost: ¥6,900,000)
|
|---|
| Research Abstract |
Investigation on potential applicability of proton beam radiotherapy for treatment of locally advanced and deep-seated tumors.
In proton beam radiotherapy improved dose distribution of radiation is accomplished so that a higher dose can be administered to the tumor while a lesser dose is given to the normal tissue, and such characteristic provides definite treatment advantage over photons. In this study the value of other treatment modalities were evaluated including fast neutron therapy, brachytherapy, intraoperative radiotherapy, conformation irradiation, variously fractionated radiation, and radiotherapy combined with hyperthermia or chemotherapy. By taking into account for the results of such evaluations, clinical examples which could be successfully treated with protons were finally investigated.
The dose-volume histogram analysis has demonstrated the superiority of proton beams over conventional radiations. It was also demonstrated that accelerated short-term radiation, 'field in field' method, and unevenly fractionated radiation were of great value in proton therapy. In a clinical proton therapy at University of Tsukuba, tumors of various deep-seated organs have been treated, and impressive clinical success has been achieved in treatment of tumors of the head and neck, lung, esophagus, liver, uterine cervix, bladder and prostate. In contrast to other radiotherapeutic modalities, proton beam radiotherapy is considered to be valuable in : (1) radical treatment of stage IIIb uterine cervix ca, locally advanced lung ca, esophagus ca, and post-operative recurrent or inoperable ca of the biliary tract, (2) pre-operative radiotherapy of rectal ca, and (3) combined treatment of protons and chemotherapy.
The above accomplishment obtained in this study has stimulated us to design a dedicated proton therapy facility.
|
